Yissum - Research Development Company of the Hebrew University

Novel Transdermal Delivery System of Cannabinoids

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Cannabinoids Transdermal, enhanced and modulated administration due to an innovative biphasic composition
Project ID : 6-2016-4334

Description of the technology

Oral Dosage Form for Immediate and Prolonged Action of Cannabinoids

Categories

Cannabinoids, Drug Delivery, Novel Carrier, Oral Formulation

Development Stage

In-vivo proof of concept

Patent Status

PCT patent application filed

Market

Improved Delivery of Cannabinoids is a real need and has increasing demand

Background

  • There is a need for products containing cannabinoids for oral administration that show a prolonged effective action. Currently, Cannabinoids are administrated in capsules or sublingual spray, the drug having only short action (a peak effect up to 4 hours with a median T max up to 2.5 hours).
  • Cannabinoids are very lipophilic molecules.Hence, in order to bring them to a molecular state (dissolved), solvents like vegetable oils, glycols (propylene glycol) and ethanol are used.
  • We have designed a new dosage form for oral administration of cannabinoids that can be used for treatment of various ailments including pain, neurological diseases, sleep, appetite, mood, anxiety, rheumatic arthritis, inflammatory diseases, and stress.

Highlights

  • Our new Oral Delivery platform for Cannabinoids does not require oils or chemical solvents.
  • Eco-friendly preparation process, no need of high heating or use of solvents.
  • The inactive ingredients used in this new dosage form are approved for pharmaceutical use
  • The technology is adequate for various cannabinoids: CBG, CBC, CBD, THC, iso-THC, CBN, CBE, CBL, CBT and their mixtures or for plant extracts.
  • In-vivo proof of concept

Our Innovation

  • We evaluated the prolonged anti-nociceptive effect of cannabinoid administered orally from the new formulation in animal pain mice model as compared to untreated animals.
  • The results of this experiment indicate that cannabinoid administration to mice from the new oral formulation lead to a rapid and prolonged significant analgesic effect starting from the first hour andreaching high MPE (Maximum Possible Effect) values:77% at the first hour and maintained at 60% up to 10 hours and 49.4% at 12 hours

Key Features

  • Oral Delivery of CBD
  • Excipients approved for pharmaceutical use
  • Eco-friendly process
  • Anti-nociceptive (very efficient and prolonged pain management) effect in animal model of cannabinoid in the new oral formulation

Development Milestones

Seeking investment in new company or industrial collaboration for the development,

Contact

Prof. Elka Touitou

Institute for Drug Research, The School of Pharmacy, Jerusalem, Israel

Project manager

Ariela Markel
VP, Business Development, Healthcare

Project researchers

Elka Touitou
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.